NCT05725096 Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population
| NCT ID | NCT05725096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhang longjiang,MD |
| Condition | Statin |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,400 participants |
| Start Date | 2023-06-28 |
| Primary Completion | 2025-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,400 participants in total. It began in 2023-06-28 with a primary completion date of 2025-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.
Eligibility Criteria
Inclusion Criteria: 1. Nanjing residents who have no plans to leave in the next 5 years 2. Aged from 40 to 69 years 3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form Exclusion Criteria: 1. Serious liver dysfunction, defined as AST or ALT \> 3 times the normal upper limit 2. Chronic kidney disease (CKD) \> stage 4, defined as eGFR \< 30 ml/min/1.73 m2 3. Prior CCTA or invasive coronary angiography within the last 5 years 4. Any contraindications for CCTA 5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang) 6. Life expectancy \< 3 years 7. Other reasons the researcher deems inappropriate to attend
Contact & Investigator
Trail Manager
STUDY CHAIR
Jinling Hospital,Nanjing University School of Medicine,Nanjing,China
Frequently Asked Questions
Who can join the NCT05725096 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 69 Years, studying Statin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05725096 currently recruiting?
Yes, NCT05725096 is actively recruiting participants. Contact the research team at kevinzhlj@163.com for enrollment information.
Where is the NCT05725096 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05725096 clinical trial?
NCT05725096 is sponsored by Zhang longjiang,MD. The principal investigator is Trail Manager at Jinling Hospital,Nanjing University School of Medicine,Nanjing,China. The trial plans to enroll 3,400 participants.